JP2019508370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508370A5 JP2019508370A5 JP2018532465A JP2018532465A JP2019508370A5 JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5 JP 2018532465 A JP2018532465 A JP 2018532465A JP 2018532465 A JP2018532465 A JP 2018532465A JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- ccl20
- level
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021172872A JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Il23アンタゴニストに対する臨床応答の予測因子としてのccl20 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271156P | 2015-12-22 | 2015-12-22 | |
| US62/271,156 | 2015-12-22 | ||
| PCT/US2016/067120 WO2017112536A1 (en) | 2015-12-22 | 2016-12-16 | Ccl20 as a predictor of clinical response to il23-antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021172872A Division JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Il23アンタゴニストに対する臨床応答の予測因子としてのccl20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508370A JP2019508370A (ja) | 2019-03-28 |
| JP2019508370A5 true JP2019508370A5 (cg-RX-API-DMAC7.html) | 2020-06-25 |
Family
ID=59091179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532465A Pending JP2019508370A (ja) | 2015-12-22 | 2016-12-16 | Il23アンタゴニストに対する臨床応答の予測因子としてのccl20 |
| JP2021172872A Pending JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Il23アンタゴニストに対する臨床応答の予測因子としてのccl20 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021172872A Pending JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Il23アンタゴニストに対する臨床応答の予測因子としてのccl20 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11220541B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3393515A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2019508370A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180096633A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108472367A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016379157A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018012626A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3007098A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL259704A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018007589A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2018124603A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017112536A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| MX2018003376A (es) | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
| HUE063462T2 (hu) | 2018-09-24 | 2024-01-28 | Janssen Biotech Inc | A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel |
| CN108957014A (zh) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | 结直肠癌血清标志物、表达评估方法、试剂盒及应用 |
| EP3946592A4 (en) * | 2019-03-26 | 2023-01-04 | Astrazeneca Collaboration Ventures, LLC | PATIENT POPULATIONS LIKELY TO BENEFIT FROM IL23 ANTAGONIST THERAPY |
| KR20230165746A (ko) | 2020-11-30 | 2023-12-05 | 민데라 코포레이션 | 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이 |
| CN113092652B (zh) * | 2021-03-19 | 2022-09-30 | 浙江工商大学 | 一种用于评估个体过敏程度的试剂盒 |
| CN114113630B (zh) * | 2021-11-24 | 2023-07-28 | 中南大学湘雅医院 | Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5455160A (en) | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| DE69731103T2 (de) | 1996-11-01 | 2005-11-17 | Fagerhol, Magne K., Dr. | Verfahren zur proteinextraktion |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ZA986596B (en) | 1997-07-25 | 1999-02-08 | Schering Corp | Mammalian cytokine related reagents |
| EP1756138A4 (en) | 2004-03-05 | 2009-07-01 | Archemix Corp | APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES |
| CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| CA2613818C (en) | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| SI1937721T1 (sl) | 2005-08-25 | 2010-11-30 | Lilly Co Eli | Anti il protitelesa |
| ME02705B (me) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| JP2009518314A (ja) | 2005-12-02 | 2009-05-07 | ジェネンテック・インコーポレーテッド | Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法 |
| SI3219328T1 (sl) | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス, インコーポレイテッド | Il−17およびil−23アンタゴニストならびにその使用方法 |
| CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| KR20100124326A (ko) | 2008-03-14 | 2010-11-26 | 엑사젠 다이어그노스틱스, 인코포레이티드 | 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커 |
| WO2010027766A1 (en) | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| EP2347256A4 (en) | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFY BIOMARKERS FOR STOMACH DISEASES |
| EP2352762A1 (en) | 2008-11-03 | 2011-08-10 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| WO2010115786A1 (en) | 2009-04-01 | 2010-10-14 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| WO2010142534A1 (en) | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
| ES2509616T3 (es) | 2009-06-25 | 2014-10-17 | Nestec S.A. | Procedimientos de diagnóstico del síndrome del intestino irritable |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CA2781654A1 (en) | 2009-11-25 | 2011-06-03 | Hua Gong | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| SI2523688T1 (en) | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| JP5972871B2 (ja) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗il−23ヘテロ二量体特異的抗体 |
| US8541180B1 (en) | 2010-10-11 | 2013-09-24 | Genova Diagnostics, Inc. | Compositions and methods for assessing gastrointestinal health |
| KR102049223B1 (ko) | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23 항체 |
| JP6116485B2 (ja) | 2011-01-06 | 2017-04-19 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 心臓性突然死に関連する方法において使用するためのscn5aスプライスバリアント |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| WO2013152114A1 (en) | 2012-04-03 | 2013-10-10 | The Regents Of The University Of Michigan | Biomarker associated with irritable bowel syndrome and crohn's disease |
-
2016
- 2016-12-16 WO PCT/US2016/067120 patent/WO2017112536A1/en not_active Ceased
- 2016-12-16 AU AU2016379157A patent/AU2016379157A1/en not_active Abandoned
- 2016-12-16 CN CN201680075323.4A patent/CN108472367A/zh active Pending
- 2016-12-16 BR BR112018012626A patent/BR112018012626A2/pt not_active Application Discontinuation
- 2016-12-16 CA CA3007098A patent/CA3007098A1/en not_active Abandoned
- 2016-12-16 JP JP2018532465A patent/JP2019508370A/ja active Pending
- 2016-12-16 KR KR1020187017346A patent/KR20180096633A/ko not_active Withdrawn
- 2016-12-16 MX MX2018007589A patent/MX2018007589A/es unknown
- 2016-12-16 RU RU2018124603A patent/RU2018124603A/ru not_active Application Discontinuation
- 2016-12-16 US US16/063,803 patent/US11220541B2/en active Active
- 2016-12-16 EP EP16879907.0A patent/EP3393515A4/en not_active Withdrawn
-
2018
- 2018-05-30 IL IL259704A patent/IL259704A/en unknown
-
2021
- 2021-10-22 JP JP2021172872A patent/JP2022031643A/ja active Pending
- 2021-11-29 US US17/536,663 patent/US20220144935A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535394A5 (cg-RX-API-DMAC7.html) | ||
| RU2018113694A (ru) | Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 | |
| RU2018124603A (ru) | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 | |
| Yamamoto et al. | Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases | |
| Ha et al. | Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis | |
| JP2023508165A5 (cg-RX-API-DMAC7.html) | ||
| CN111133313A (zh) | 评估生物药物治疗的受试者中的中和性抗体水平的测定及其在个性化医疗中的用途 | |
| Lee et al. | Isolated anti-Ro52 identifies a severe subset of Sjögren’s syndrome patients | |
| JP2016128441A5 (cg-RX-API-DMAC7.html) | ||
| EP3077818B1 (en) | Methods for predicting post-operative recurrence of crohn's disease | |
| CN104838270A (zh) | 用于预测和监测粘膜愈合的方法 | |
| BR112016005745B1 (pt) | Biomarcadores para tuberculose | |
| Chen et al. | Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis | |
| TWI655433B (zh) | 川崎氏症之診斷與治療 | |
| Fouladseresht et al. | Anti-varicella zoster virus IgG and hsCRP levels correlate with progression of coronary artery atherosclerosis | |
| Jocić et al. | Interleukin 41 as a potential predictor of bio-therapy efficacy in patients with rheumatoid arthritis: A prospective observational study | |
| Liao et al. | Association of C-type lectin 18 levels with extrahepatic manifestations in chronic HCV infection | |
| WO2015166461A1 (en) | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels | |
| Gong et al. | Serum progranulin levels are elevated in patients with chronic hepatitis B virus infection, reflecting viral load | |
| Ra et al. | Kinetics of Serological Response in Patients with Severe Fever with Thrombocytopenia Syndrome. Viruses 2021, 13, 6 | |
| Kelvin | Ethan B. Jansen, Ali Toloue Ostadgavahi 3, Benjamin Hewins 3, Rachelle Buchanan, Brittany M. Thivierge, Gustavo Sganzerla Martinez 3, Una Goncin 4, Magen E. Francis, Cynthia L. Swan, Erin Scruten, Jack Bell, Joseph Darbellay, Antonio Facciuolo, Darryl Falzarano, Volker Gerdts, Mark E. Fenton 6, Peter Hedlin 4, David J. Kelvin 3 & | |
| Hussein et al. | Clinical Relevance Of Anti-Cyclic Citrullinated Peptide Antibodies In Rheumatoid Arthritis | |
| Zer et al. | PVI-25 The effect of autoantibodies to test results in patients with low-titre anti-HCV positivity | |
| Halicioglu et al. | PVI-26 Hepatitis A seroprevalence in pediatric patients in west part of Turkey | |
| Liyan et al. | The relationship between IL-10 levels, gene polymorphisms and |